Clinical Trial: FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

U.S., Oct. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07216105) titled 'FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors' on Oct. 08.

Brief Summary: This is a phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of FT836 with or without paclitaxel and/or trastuzumab or cetuximab, and to determine the recommended phase 2 dose (RP2D) of FT836 in combination with trastuzumab or cetuximab; each objective will be assessed with or without paclitaxel chemotherapy.

Study Start Date: Oct. 30

Study Type: INTERVENTIONAL

Condition: Non-Small Cell L...